ANI Pharmaceuticals
As of the edition of 20 October 2026, ANI Pharmaceuticals runs 23 drugs, 23 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
ANI Pharmaceuticals was renamed in 2005.
The records place 3 company names in this family.
- ANI Pharmaceuticals, Inc.: renamed in 2005
- Alimera Sciences: acquired in 2024; successor ANI Pharmaceuticals, Inc.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 23 |
| Total | 23 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Hydroxychloroquine | none listed | 0 |
| Anastrozole | none listed | 1 |
| Hydrocortisone | none listed | 5 |
| Hydrochlorothiazide | none listed | 4 |
| Estradiol | Ends 2032 (patent) | 6 |
| Propranolol | none listed | 4 |
| Testosterone | none listed | 4 |
| Vancomycin | none listed | 0 |
| Bicalutamide | none listed | 1 |
| Corticotropin | none listed | 1 |
| Metoclopramide | none listed | 3 |
| Lithium carbonate | none listed | 3 |
| Fluvoxamine | none listed | 3 |
| Candesartan cilexetil | none listed | 2 |
| Fluocinolone acetonide | none listed | 1 |
| Sinecatechins | none listed | 0 |
| Promethazine | none listed | 1 |
| Terbutaline | none listed | 0 |
| Terazosin | none listed | 3 |
| Diethylpropion | none listed | 1 |
| Oxiconazole | none listed | 0 |
| Hydrocortisone probutate | none listed | 0 |
| Corticotropin zinc hydroxide | none listed | 0 |
A route B row is one company at one target.